An interventional study of Guduchi Ghan Vati in Covid19, sponsored by Aarogyam UK. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-09.
Sponsored by Aarogyam UK · Not applicable, Interventional, and Treatment
The emergence of asymptomatic patients poses a significant challenge to the prevention and treatment of the epidemic.There have not been any treatment options that reduce the viral load or preventive options that reduce the risk of developing severe conditions.Therefore, present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in asymptomatic patients with COVID-19
7,641 studies on the registry are indexed under COVID-19; 487 are open to participants now.
This study's enrollment of 46 is below the median of 100 across 4,100 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Aarogyam UK is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Guduchi Ghana is a unique Ayuvedic classical preparation prepared from aqueous extracts of Tinospora cordifolia stem.
Drug: Guduchi Ghan Vati
Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
Also known as: Giloya, Amrita, Tinosporia Cordifolus, Guduchi
Virologic clearance
Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result
Time frame: 14 days
Hospital Stay
Total duration of stay in hospital for complete recovery
Time frame: 14 days
Clinically relevant adverse effects
Clinically relevant adverse effects of Guduchi Ghan Vati were reported using Adverse Drug Reaction reporting form
Time frame: 14 days
Laboratory tests
Routine blood tests were performed to assess complete blood counts, blood biochemistry parameters {Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Urea, C-reactive protein (CRP), as well as Albumin} and immunoglobulines.
Time frame: change from baseline to 14 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarogyam UK